Q3 Revenue Jumps 33% to $21M as Restructuring Extends Cash Runway Into 2029
ADCT has more than doubled off its 52-week low of $0.78.
Summary
Net product revenue rose to $21.7 million from $15.8 million a year ago on higher volume, and the net loss narrowed to $25.3 million ($0.16 per share) from $41.0 million ($0.30), with an adjusted loss per share of 6 cents. Total operating expenses fell 24% to $36.1 million as R&D dropped to $14.7 million from $26.8 million after discontinued programs. Cash stood at $189.2 million on September 30, and management reiterated a runway into 2029 following the October restructuring that brought in an $86.6 million PIPE and cut term-loan principal to $50 million. The Japan path is advancing: partner Tanabe filed a marketing authorization application and sublicensed commercialization to Nippon Shinyaku, which supports milestone payments. The overhang remains LOTIS-5 — the FDA raised serious benefit-risk concerns at the pre-sBLA meeting in August, and full Phase 3 data plus five oral presentations land at ASH in December, the key read for whether accelerated approval holds.
At the time of this announcement, ADCT was trading at $1.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $201.7M. The 52-week trading range was $0.78 to $4.98. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.